Major
Biotechnology
Research Abstract
The need to develop a robust method to produce large quantities of plasmid DNA has become vital due to the strides made in the field of gene therapy. More and more biopharmaceutical companies are starting to produce gene therapeutics to treat diseases at the molecular level. While the technology has been proven to work and success at treating disease using gene therapeutics have been made in clinical trials, a method to produce large quantities of DNA still remains a challenge. In this presentation, I will go over some of the current challenges associated with producing high copy numbers of plasmid DNA and some of upstream process development improvements that have been made to generate larger quantities of plasmid DNA.
Faculty Mentor/Advisor
Cary Lai
Included in
Plasmid DNA Upstream Manufacturing Process Development
The need to develop a robust method to produce large quantities of plasmid DNA has become vital due to the strides made in the field of gene therapy. More and more biopharmaceutical companies are starting to produce gene therapeutics to treat diseases at the molecular level. While the technology has been proven to work and success at treating disease using gene therapeutics have been made in clinical trials, a method to produce large quantities of DNA still remains a challenge. In this presentation, I will go over some of the current challenges associated with producing high copy numbers of plasmid DNA and some of upstream process development improvements that have been made to generate larger quantities of plasmid DNA.
